Eisai’s Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eisai has pushed back the filing of its novel AMPA receptor antagonist perampanel for Parkinson's disease from fiscal 2007 to fiscal fourth quarter 2008 (ended March 31, 2009) in the U.S. and Europe because the drug failed to show an efficacy benefit over placebo in a Phase III study, Eisai said Oct. 30
You may also be interested in...
Eisai Drops Perampanel In Parkinson's, Plans Neuropathy Submission In 2010
Development focus shifts after second failed Phase III trial in Parkinson’s disease. New studies in neuropathic pain and epilepsy employ doses up to 12 mg, compared to 2 mg and 4 mg doses in Parkinson’s studies
Eisai Drops Perampanel In Parkinson's, Plans Neuropathy Submission In 2010
Development focus shifts after second failed Phase III trial in Parkinson’s disease. New studies in neuropathic pain and epilepsy employ doses up to 12 mg, compared to 2 mg and 4 mg doses in Parkinson’s studies
Eisai’s 2008 Eribulin NDA Plan Foiled; Beaten To The Punch By Ixempra
FDA has dealt a setback to Eisai's burgeoning oncology pipeline by denying the company's efforts to seek accelerated approval for its microtubule growth suppressor E7389 (eribulin mesylate)